Announcement on the Implementation of Profit Distribution of Jianfeng Group in 2013
Release time:
2020-08-05
证券代码：600668证券 简称：尖峰集团 公告编号：临 2014-019
债券简称：13 尖峰 01 债券代码：122227
浙江尖峰集团股份有限公司 2013 年度利润分配实施公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示：
● 扣税前与扣税后每股现金红利
每股现金红利（扣税前）0.171 元
每股现金红利（扣税后 0.18 元
● 股权登记日 2014 年 7 月 24 日
● 除权（除息）日 2014 年 7 月 25
● 现金红利发放日 2014 年 7 月 25 日
一、 通过分配、转增股本方案的股东大会届次和时间
浙江尖峰集团股份有限公司 2013 年度利润分配预案经 2014 年 6 月 6 日召开的公司
2013 年度股东大会审议通过。股东大会决议公告刊登于 2014 年 6 月 7 日的 《中国证券 报》、《上海证券报》以及上海证券交易所网站（http://www.sse.com.cn）。
二、分配方案 (一)发放年度：2013 年度 (二)发放范围：
截止 2014 年 7 月 24 日下午在上海证券交易所收市后，在中国证券登记结算有限责 任公司上海分公司(以下简称：中登上海分公司)登记在册的本公司全体股东。
本次分配以 2013 年末股本 344,083,828 股为基数，向全体股东每 10 股派发现金红
利 1.8 元（含税），扣税后每 10 股派发现金红利 1.71 元。共计派发股利 61935089.04 元。 (三) 扣税说明 1、对于个人股东（包括证券投资基金）的现金红利，根据《关于实施上市公司股息
红利差别化个人所得税政策有关问题的通知》（财税〔2012〕85 号）有关规定，公司暂 按 5%的税率代扣个人所得税，扣税后实际每股派发现金红利 0.171 元。如股东的持股期 限在 1 个月以内（含 1 个月）的，其股息红利所得全额计入应纳税所得额，实际税率 20%；
持股期限在 1 个月以上至 1 年（含 1 年）的，实际税率 10%；持股期限超过 1 年的，实际 税率 5%。个人（包括证券投资基金）转让股票时，中登上海分公司根据其持股期限计算 实际应纳税额，超过已扣缴税款的部分，由证券公司等股份托管机构从个人资金账户中扣 收并划付中登上海分公司，中登上海分公司于次月 5 个工作日内划付公司，公司在收到税 款当月的法定申报期内向主管税务机关申报缴纳。
2、对于合格境外机构投资者（QFII）的现金红利，根据《关于中国居民企业向 QFII 支付股息、红利、利息代扣代缴企业所得税有关问题的通知》（国税函〔2009〕47 号）
（以下简称“《通知》”）相关规定，由公司按 10%的税率代扣代缴企业所得税，扣税后 实际每股派发现金红利 0.162 元。如相关股东认为其取得的股息收入需要享受任何税收协 定（安排）待遇的，股东可按照《通知》的规定在取得股息后自行向主管税务机关提出申 请。
3、对于属于《企业所得税法》项下居民企业含义的公司股东(含机构投资者)，其所 得税自行缴纳，实际派发现金红利为每股人民币 0.18 元。
三、 分配方案实施日期
(一) 股权登记日 2014 年 7 月 24 日
(二)除权（除息）日 2014 年 7 月 25 日
(三)现金红利发放日 2014 年 7 月 25 日
四、分派对象
截止 2014 年 7 月 24 日（股权登记日）下午上海证券交易所收市后，在中国证券登 记结算有限责任公司上海分公司登记在册的本公司全体股东。
五、 分红、转增股本实施办法
（一）本公司股东金华市通济国有资产投资有限公司的现金红利由本公司直接发放。
（二）除金华市通济国有资产投资有限公司以外的本公司其他股东的现金红利，本 公司委托中登上海分公司通过其资金清算系统向股权登记日登记在册并在上海证券交易 所各会员办理了指定交易的股东派发。已办理全面指定交易的投资者可于红利发放日在其 指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中登上海分公司保管， 待办理指定交易后再进行派发。
六、 有关咨询办法
地址：浙江省金华市婺江东路 88 号尖峰大厦董事会办公室 电话：0579-82324699；传真：0579-82324699
七、 备查文件目录
本公司 2013 年度股东大会决议及公告。
浙江尖峰集团股份有限公司
董事会
2014 年 7 月 21 日
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page